Cargando…

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma

Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR) pathway, is currently approved for treatment of advanced renal-cell carcinoma (RCC) after failure of initial treatment with the tyrosine kinase inhibitors. Patients with tuberous sclerosis complex (TSC) syndrome can also devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsidawi, Samer, Kasi, Pashtoon Murtaza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2018
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880255/ https://www.ncbi.nlm.nih.gov/pubmed/29610387 http://dx.doi.org/10.1101/mcs.a002220

Ejemplares similares

Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy
por: Ni, Jianxin, et al.
Publicado: (2019)

Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
por: Luo, Cong, et al.
Publicado: (2021)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
por: Kasi, Pashtoon Murtaza
Publicado: (2022)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Everolimus induced organizing pneumonia in a patient with tuberous sclerosis complex
por: Lanfranco, Julio, et al.
Publicado: (2021)

Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex
por: Daccord, Cécile, et al.
Publicado: (2020)

Renal Cell Carcinoma in Tuberous Sclerosis Complex
por: Henske, Elizabeth P., et al.
Publicado: (2021)

The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report
por: Kim, Hye Sook, et al.
Publicado: (2014)

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()
por: Gipson, Tanjala T., et al.
Publicado: (2013)

Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
por: Robles, Nicolás Roberto, et al.
Publicado: (2016)

Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial
por: Cai, Yi, et al.
Publicado: (2018)

Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus
por: Zonnenberg, Bernard A., et al.
Publicado: (2018)

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2
por: Bissler, John J, et al.
Publicado: (2019)

Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma
por: Gau, Shuo-Yan, et al.
Publicado: (2023)

A Chinese Tuberous Sclerosis Complex Family and a Novel Tuberous Sclerosis Complex-2 Mutation
por: Luo, Rong, et al.
Publicado: (2015)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

The Effect of Everolimus on Subependymal Giant Cell Astrocytoma (SEGA) in Children with Tuberous Sclerosis Complex
por: BAKHTIARY, Hassan, et al.
Publicado: (2021)

Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study
por: Gu, Liangyou, et al.
Publicado: (2021)

Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex
por: Shoji, Tetsuaki, et al.
Publicado: (2021)

Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
por: Moloney, Patrick B., et al.
Publicado: (2021)

Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation
por: Hwang, Su-Kyeong, et al.
Publicado: (2016)

Everolimus Reduces the Size of Tuberous Sclerosis Complex-Related Huge Renal Angiomyolipomas Exceeding 20 cm in the Longest Diameter
por: Toriu, Naoya, et al.
Publicado: (2018)

Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex
por: Agarwal, Shubhangi, et al.
Publicado: (2022)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Renal Manifestations of Tuberous Sclerosis Complex
por: Nair, Nikhil, et al.
Publicado: (2020)

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
por: Capal, Jamie K, et al.
Publicado: (2016)

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
por: Davies, Mark, et al.
Publicado: (2017)

Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia
por: Leitner, Dominique F., et al.
Publicado: (2022)

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice
por: Cockerell, Ine, et al.
Publicado: (2023)

Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

A Multi-Centric Study Assessing Safety and Efficacy of Everolimus in Adult Chinese Patients With Tuberous Sclerosis Complex Associated Renal Angiomyolipomas
por: Wang, Wenda, et al.
Publicado: (2022)

A Case of Tuberous Sclerosis Complex with Lymphangioleiomyomatosis and Renal Cell Carcinoma
por: Wu, Yun, et al.
Publicado: (2020)

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Erratum: Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019)

Malignancy of renal angiomyolipoma from tuberous sclerosis complex with TSC2 mutation
por: Huang, Yu-Jing, et al.
Publicado: (2019)

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
por: Franz, David Neal
Publicado: (2013)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hnttgcqbob3ohkbvapri3656sa